CN109444427A - A kind of kit detecting human parvovirus IgM antibody - Google Patents
A kind of kit detecting human parvovirus IgM antibody Download PDFInfo
- Publication number
- CN109444427A CN109444427A CN201811518116.9A CN201811518116A CN109444427A CN 109444427 A CN109444427 A CN 109444427A CN 201811518116 A CN201811518116 A CN 201811518116A CN 109444427 A CN109444427 A CN 109444427A
- Authority
- CN
- China
- Prior art keywords
- igm
- magnetic particle
- kit
- liquid
- human parvovirus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/75—Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated
- G01N21/76—Chemiluminescence; Bioluminescence
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
- G01N33/54326—Magnetic particles
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/01—DNA viruses
- G01N2333/015—Parvoviridae, e.g. feline panleukopenia virus, human Parvovirus
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Medicinal Chemistry (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Virology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Tropical Medicine & Parasitology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Plasma & Fusion (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The invention discloses a kind of kits for detecting human parvovirus IgM antibody, including B19-IgM magnetic particle suspension, magnetic particle B19-IgM enzyme conjugates, magnetic particle B19-IgM sample diluting liquid, magnetic particle B19-IgM calibration object, luminous substrate and concentration washing lotion；It is 0.05-1um magnetic particle that wherein the solid phase carrier in B19-IgM magnetic particle suspension, which is carboxylated partial size, and coated antibody is mouse Anti-human IgMμ chain monoclonal antibody；The enzyme-labelled antigen of the magnetic particle B19-IgM enzyme conjugates is the gene recombinant antigens of horseradish peroxidase-labeled.Kit of the present invention can test and analyze sample using Full-automatic chemiluminescence analyzer, have many advantages, such as that easy to operate, detection time is short, testing result is accurate, the detection range of linearity is wide.
Description
Technical field
The present invention relates to in-vitro diagnosis immunoassay technologies, more particularly, to a kind of detection human parvovirus IgM antibody
Kit.
Background technique
Human parvovirus B19 (HPVB19) is linear ssdna virus, and Genome Size 5.6kb is classified as thin
The red Tobamovirus of small virus subfamily.Blood product, 2-7 years old children are the major source of infection of HPV B19 virus, respiratory tract, blood system
Product and vertical transmission are its common routes of transmission.HPV B19 infection is all over the world, according to age and Regional Distribution, sense
Dye rate is not identical.About 15% preprimary child, 50% adult and 85% the elderly's positive serology.HPV B19 generally draws
Self-limited disease is played, infection symptoms are different and different because the immune function of host and hematology constitution.Infected children is most typical
Symptom is erythema infectioum (the 5th disease)；It is arthritis and arthralgia that adult B19, which infects the most common symptom,；Infection of pregnant women B19
It will lead to fetus edema and fetus anaemia, can lead to miscarriage when serious, HPV B19 is considered as the intrauterine infection for being only second to HCMV
The body one of most important cause of disease；For immune deficiency patient, such as AIDS patient, the cancer for receiving chemotherapy or organ transfer operation
Patient cannot generate neutralizing antibody after infecting B19 due to lead to chronic anaemia, of short duration aplastic crisis and acute leaching
The serious diseases such as bar leukaemia, can lead to death when serious.
Antibody test is the main method of current clinical diagnosis and epidemiological survey B19 infection, and detection method mainly has
ELISA and colloidal gold, shortcoming have the following: 1, hand-manipulated, sample-adding is inaccurate；Operating time is long, process is cumbersome,
Bust easily occurs；These errors and mistake will affect the accuracy and precision of testing result.2, detection process is in
Open space easily causes the cross contamination between various reagents, and then influences the accuracy of testing result.3, in methodology
Colloidal gold sensitivity for analysis is low, and there is also human errors for naked eyes interpretation result.It 4, is all qualitative product, the range of linearity is narrow；It is qualitative
Product is determined with a simple color reaction point as a result, being easy to produce false positive or false negative result.
The study found that generating IgM or IgG in vivo is a urgency since primary infection or recurrent infection occur for the gestational period
The process of drastic change only can just be detected by the variation of quantitative analysis concentration, and quantitative analysis also contributes to discovery false positive
Or false negative result, so quantitative analysis is the optimal selection of TORCH screening.
Summary of the invention
The purpose of the present invention is to provide a kind of reagents that human parvovirus IgM antibody is detected using chemoluminescence method
Box, the kit can quantitative detection B19-IgM antibody level, the dynamic monitoring applied to IgM antibody level.
To achieve the above object, the present invention can take following technical proposals:
The kit of detection human parvovirus IgM antibody of the present invention, including B19-IgM magnetic particle suspension, magnetic particle
B19-IgM enzyme conjugates, magnetic particle B19-IgM sample diluting liquid, magnetic particle B19-IgM calibration object, luminous substrate and concentration are washed
Liquid；It is 0.05-1um magnetic particle that wherein the solid phase carrier in B19-IgM magnetic particle suspension, which is carboxylated partial size, and coated antibody is
The anti-human IgM μ chain monoclonal antibody of mouse；The enzyme-labelled antigen of the magnetic particle B19-IgM enzyme conjugates is horseradish peroxidase mark
The gene recombinant antigens of note.
In the B19-IgM magnetic particle suspension envelope protect liquid be PH7~8 PBS buffer solution, wherein containing preservative,
Protein-based stabilizer, surfactant and glycerol.
The magnetic particle B19-IgM sample diluting liquid is the Tris buffer of PH7~8, wherein containing preservative, protein
Class stabilizer and surfactant.
The magnetic particle B19-IgM calibration object is by the dilution preparation of the B19-IgM high level positive between 0~240AU/mL
6 various concentration points；The magnetic particle B19-IgM calibration object can also be diluted by the B19-IgM high level positive prepare 0~
6 various concentration points between 120AU/mL；Calibration object dilution used is the Tris buffer of PH7~8, wherein containing anti-
Rotten agent, protein-based stabilizer and surfactant.
Wherein: the envelope of B19-IgM magnetic particle suspension protects in liquid, in magnetic particle B19-IgM sample diluting liquid and magnetic is micro-
Preservative described in grain B19-IgM calibration object is preservative Proclin300, MIT, Bro, IPBC or NaN3One of
Or two or more mixtures；The protein-based stabilizer is one of casein, isinglass or bovine serum albumin(BSA) or two
Kind or more mixture；The surfactant is Triton X-100, in Tween20, Tween60 or octyl phenol polyoxyethylene ether
One or more kinds of mixtures.
Luminous substrate used in the present invention includes luminous substrate A liquid and B liquid；Wherein luminous substrate A liquid is by 0.2M Tris-
Hcl, 0.15mM Luminol, 0.59mM Hydroxycoumarin, 0.59mM gallic acid are formulated；Luminous substrate B liquid by
0.2M acetic acid-acetate buffer, 0.85mM amino acid oxidase, 0.008 Tween20,0.5mM diethylene triamine pentacetic acid (DTPA),
0.12mM vitamin C is formulated.
Concentration washing lotion used in the present invention is 10 times of concentration washing lotions, by NaH2PO4·2H2O 4.6g、Na2HPO4·12H2O
62.32g, NaCl 175.6g, 20 2-10ml of Tween, distilled water 1000ml are formulated.
Kit of the present invention can test and analyze sample using Full-automatic chemiluminescence analyzer, have operation letter
Just, the advantages that detection time is short, testing result is accurate, the detection range of linearity is wide.
Specific embodiment
More detailed explanation is done to the present invention below by specific embodiment, to facilitate the reason of those skilled in the art
Solution.Unless otherwise specified, reagent used in the present embodiment and detecting instrument are commercial product, and method is industry routine side
Method.
The kit of the preparation detection human parvovirus IgM antibody of embodiment 1
1, B19-IgM magnetic particle suspension is prepared
1.1 take the carboxyl surface magnetic bead stoste after 30ul mixing to be washed 5 times with the PBS buffer solution of 300ul.
1.2 activate magnetic particle 1 hour with the NHS of the EDC and 20mg/ml of 20mg/ml.
1.3, which buffer B liquid with PH 4.75, washs the magnetic particle after activation 3 times.
1.4 are added the anti-human IgM μ chain monoclonal antibody of mouse according to the amount of 0.25ug/ test, are coated with 2 hours.
1.5, which protect fluid-tight with envelope, closes 4 times.
1.6, which are added 3ml envelope, protects liquid preservation.
Envelope used in it, which protects liquid, to be prepared by the PBS buffer solution of PH7~8 of 0.01M, wherein anti-containing 1 ‰ (v/v)
The Liquid BPF aN of rotten agent Proclin 300,0.2 ‰ (w/v)3, 3%(w/v) and stabilizer bovine serum albumin(BSA), the table of 1 ‰ (v/v)
Face activating agent Triton X-100,5%(v/v) glycerol.
2, magnetic particle B19-IgM enzyme conjugates is prepared
The B19 gene recombinant antigens of horseradish peroxidase-labeled are arrived according to the dilution proportion of volume ratio 1:1000~1:2000
In enzyme conjugates buffer, enzyme conjugates solution is obtained；
Enzyme conjugates buffer used by 0.05M PH7~8 Tris buffer, wherein anti-containing 1 ‰ (v/v)
The preservative Bro, 20%(v of rotten agent Proclin 300,0.2 ‰ (w/v)/v) stabilizer cow's serum, the surface of 1 ‰ (v/v) are living
Property agent Triton X-100,0.2 ‰ carmine pigment.
3, magnetic particle B19-IgM sample diluting liquid is prepared
Sample diluting liquid by 0.01M PH7~8 Tris buffer, wherein contain 1 ‰ (v/v) preservative Proclin
300, the Liquid BPF aN of 0.2 ‰ (w/v)3, 2%(w/v) stabilizer bovine serum albumin(BSA), 1%(v/v) surfactant
Triton X-100,0.2 ‰ lemon yellow pigment, 0.2 ‰ sunset yellow.
4, magnetic particle B19-IgM calibration object is prepared
Calibration object by the B19-IgM high level positive dilution prepare 6 between 0~240AU/mL (0AU/ml, 6AU/ml,
30AU/ml, 60AU/ml, 120AU/ml, 240AU/ml) concentration point.
Dilution used is formed by the Tris buffer of PH7~8 of 0.01M, wherein anti-containing 1 ‰ (v/v)
The Liquid BPF aN of rotten agent Proclin 300,0.2 ‰ (w/v)3, 2%(w/v) and stabilizer bovine serum albumin(BSA), 0.2 ‰ lemon
Uranidin, 0.2 ‰ sunset yellow.
5, luminous substrate is prepared
Luminous substrate A liquid is not eaten by 0.2M Tris-Hcl, 0.15mM Luminol, 0.59mM Hydroxycoumarin, 0.59mM
Sub- acid is formulated；
Luminous substrate B liquid by 0.2M acetic acid-acetate buffer, 0.85mM amino acid oxidase, 0.008 Tween20,
0.5mM diethylene triamine pentacetic acid (DTPA), 0.12mM vitamin C are formulated.
6, concentration washing lotion is prepared
Concentration washing lotion is 10 times of concentration washing lotions, by NaH2PO4·2H2O 4.6g、Na2HPO4·12H2O 62.32g、NaCl
20 2-10ml of 175.6g, Tween, distilled water 1000ml are formulated.
The application method of the kit of the present invention of embodiment 2
1. sample requires
1.1 collect whole blood sample using correct medical technology, are centrifugated after haemocyte agglomerates at room temperature, extract serum
For detecting.EDTA(1.5g/L whole blood can also be used), sodium citrate (10.9mmol/L whole blood) or heparin sodium (0.1-0.2mg/
ML whole blood) make the blood plasma of anti-coagulants for detecting.
It may not exceed 8 hours after 1.2 serum collections being placed at room temperature for.If do not detected in 8 hours, sample need to be put
It sets in 2-8 DEG C of refrigerator；If needing to save or transport for a long time, should freeze in -20 DEG C hereinafter, avoiding multigelation.It uses
Before be restored to room temperature, gently shake mixing.
2. the method for inspection
2.1 consumables inspections: illustrate load or check whether consumables are sufficient, grasp with reference to corresponding instrument system according to instrument
It explains.
2.2 reagents packaging carries: reagent packet before upper machine, lightly reverses reagent packet repeatedly to mix in novel agent packet for the first time
Ingredient, avoid generate bubble；The reagent packet having already turned on is not reversed；Instrument obtains survey by scanning reagent packet bar code automatically
Parameter needed for examination.It if instrument can not identify bar code in special circumstances, can manually enter, be grasped with reference to corresponding instrument system
It explains.
2.3 tests: sample container is placed in the mating sample rack of instrument；Sample loading frame, in instrument software interface
Input sample information；Selection " RUN " starts to test, and system carries out test operation automatically.It is said with reference to the operation of corresponding instrument system
It is bright.
3. result calculates
Curve matching mode appropriate is selected, it is x with calibration object concentration value that this kit, which is recommended to use four parameter fitting modes,
Axis establishes calibration curve using calibration object luminous intensity log value as y-axis.It is back-calculated accordingly according to the luminous intensity values of sample to be tested
Concentration value.Instrument automatic operation system can calculate automatically sample by the signal value that the calibration curve and test sample of storage obtain
This test result.
4. reference value
Determine reference value using ROC curve method: concentration of specimens value < 6AU/ml is judged to feminine gender；6AU/ml≤concentration value < 10AU/ml
It is judged to suspicious；Concentration value >=10AU/ml is judged to the positive.
Note: i.e. " arbitrary unit is translated as " arbitrary unit " to AU, is also translated into " making unit by oneself " in unit AU/ml
I.e. in the case where lacking specific, unified standard at present, internal standard that applicant voluntarily formulates, it is proposed that each laboratory root
Normal reference value is established according to itself physical condition and exposed population group.
Need specified otherwise:
In immunology diagnosis field, since the detection of IgM antibody does not have absolutely accurate reliable with reference to method at present, do not have yet
There are specific standard items that can refer to for each detection manufacturer, i.e., numerical value does not have comparativity between producer, instrument.
The performance evaluation of the kit prepared by the present invention of embodiment 3
(1) sensitivity for analysis
Product are controlled as sensitivity with 0 value calibration product, 20 hole measurements is carried out, calculates the average (M) and standard deviation of its luminous value
(SD), the concentration value of M+2SD is back-calculated according to dose-response curve, acquired results are sensitivity for analysis.
(2) linear detection:
3 parts of high level samples close to 240AU/ml are diluted to 6 kinds of concentration by 1:2,1:4,1:8,1:16,1:40, wherein low value
The sample of concentration must be close to the lower limit (6AU/ml) of the range of linearity.The sample of each concentration is repeated to detect 2 times, is calculated average
Value, carries out straight line fitting with least square method for result average value and dilution ratio, and calculate linearly dependent coefficient R, it is desirable that and R≤
0.99。
As the result is shown: in 6~240AU/ml range of linearity, the correlation coefficient r of 3 parts of samples is respectively 0.9998,
0.9998,0.9999, meet the requirements.
(3) detection of accuracy:
Detection according to intra-company trace to the source chain foundation 2 parts of enterprise's accuracy reference materials, calculate measured concentration with indicate concentration it is inclined
Difference, it is desirable that deviation is within 15%.
As the result is shown: 2 parts of enterprise's accuracy reference material detection errors are respectively less than 15%, meet the requirements.
(4) precision measures:
Repeated reference material Q1, Q2 is detected, each each concentration of sample respectively does 10 in parallel, is carried out with three batches of kits
Detection calculates kit and criticizes interior and difference between batch.
As the result is shown: in kit batch and batch variation is respectively less than 8%.
Claims (8)
1. a kind of kit for detecting human parvovirus IgM antibody, it is characterised in that: including B19-IgM magnetic particle suspension, magnetic
Particles B 19-IgM enzyme conjugates, magnetic particle B19-IgM sample diluting liquid, magnetic particle B19-IgM calibration object, luminous substrate and dense
Contracting washing lotion；It is 0.05-1um magnetic particle that wherein the solid phase carrier in B19-IgM magnetic particle suspension, which is carboxylated partial size, and coating is anti-
Body is the anti-human IgM μ chain monoclonal antibody of mouse；The enzyme-labelled antigen of the magnetic particle B19-IgM enzyme conjugates is horseradish peroxidase
The gene recombinant antigens of enzyme label.
2. the kit of detection human parvovirus IgM antibody according to claim 1, it is characterised in that: the B19-IgM
Envelope in magnetic particle suspension protects the PBS buffer solution that liquid is PH7~8, wherein containing preservative, protein-based stabilizer, surface
Activating agent and glycerol.
3. the kit of detection human parvovirus IgM antibody according to claim 1, it is characterised in that: the magnetic particle
B19-IgM sample diluting liquid is the Tris buffer of PH7~8, wherein containing preservative, protein-based stabilizer and surface-active
Agent.
4. the kit of detection human parvovirus IgM antibody according to claim 1, it is characterised in that: the magnetic particle
6 between the 0~240AU/mL various concentration point that B19-IgM calibration object is prepared by the dilution of the B19-IgM high level positive；It is used
Calibration object dilution be PH7~8 Tris buffer, wherein contain preservative, protein-based stabilizer and surfactant.
5. the kit of detection human parvovirus IgM antibody according to claim 4, it is characterised in that: the magnetic particle
6 between the 0~120AU/mL various concentration point that B19-IgM calibration object is prepared by the dilution of the B19-IgM high level positive.
6. detecting the kit of human parvovirus IgM antibody according to claim 2,3 or 4, it is characterised in that: described anti-
Rotten agent is preservative Proclin300, MIT, Bro, IPBC or NaN3One or more mixtures of；The protein
Class stabilizer is one or more mixtures of casein, isinglass or bovine serum albumin(BSA)；The surfactant
For one or more mixtures of Triton X-100, Tween20, Tween60 or octyl phenol polyoxyethylene ether.
7. the kit of detection human parvovirus IgM antibody according to claim 1, it is characterised in that: the luminous bottom
Object includes luminous substrate A liquid and B liquid；Wherein luminous substrate A liquid is by 0.2M Tris-Hcl, 0.15mM Luminol, 0.59mM
Hydroxycoumarin, 0.59mM gallic acid are formulated；Luminous substrate B liquid is by 0.2M acetic acid-acetate buffer, 0.85mM ammonia
Base acid oxidase, 0.008 Tween20,0.5mM diethylene triamine pentacetic acid (DTPA), 0.12mM vitamin C are formulated.
8. the kit of detection human parvovirus IgM antibody according to claim 1, it is characterised in that: the concentration is washed
Liquid is 10 times of concentration washing lotions, by NaH2PO4·2H2O 4.6g、Na2HPO4·12H2O 62.32g、NaCl 175.6g、Tween
20 2-10ml, distilled water 1000ml are formulated.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811518116.9A CN109444427A (en) | 2018-12-12 | 2018-12-12 | A kind of kit detecting human parvovirus IgM antibody |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811518116.9A CN109444427A (en) | 2018-12-12 | 2018-12-12 | A kind of kit detecting human parvovirus IgM antibody |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN109444427A true CN109444427A (en) | 2019-03-08 |
Family
ID=65557447
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201811518116.9A Withdrawn CN109444427A (en) | 2018-12-12 | 2018-12-12 | A kind of kit detecting human parvovirus IgM antibody |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109444427A (en) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111796105A (en) * | 2020-07-30 | 2020-10-20 | 中国农业科学院兰州兽医研究所 | Magnetic particle chemiluminescence antibody detection kit for African swine fever virus and application thereof |
| CN111999494A (en) * | 2020-08-18 | 2020-11-27 | 北京贝尔生物工程股份有限公司 | Kit for detecting adenovirus IgM antibody by magnetic particle chemiluminescence method and preparation method thereof |
| CN111999495A (en) * | 2020-08-18 | 2020-11-27 | 北京贝尔生物工程股份有限公司 | Kit for detecting Coxsackie group B virus IgM antibody by magnetic particle chemiluminescence method and preparation method thereof |
| CN112433050A (en) * | 2020-11-04 | 2021-03-02 | 上海赛罕生物技术有限公司 | Chlamydia pneumoniae IgM antibody detection kit and detection method thereof |
| CN113295862A (en) * | 2020-02-21 | 2021-08-24 | 深圳麦科田生物医疗技术股份有限公司 | Kit and method for detecting novel coronavirus SARS-CoV-2 antibody based on antigen marker |
| CN115047193A (en) * | 2022-06-27 | 2022-09-13 | 上海凯创生物技术有限公司 | Method for detecting trace amount of drugs in sewage |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2008145181A (en) * | 2006-12-07 | 2008-06-26 | Abbott Japan Co Ltd | Detecting method of parvovirus b19 |
| WO2017065261A1 (en) * | 2015-10-15 | 2017-04-20 | 富士レビオ株式会社 | Method and kit for simultaneously detecting human parvovirus b19 antigen and antibody |
-
2018
- 2018-12-12 CN CN201811518116.9A patent/CN109444427A/en not_active Withdrawn
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2008145181A (en) * | 2006-12-07 | 2008-06-26 | Abbott Japan Co Ltd | Detecting method of parvovirus b19 |
| WO2017065261A1 (en) * | 2015-10-15 | 2017-04-20 | 富士レビオ株式会社 | Method and kit for simultaneously detecting human parvovirus b19 antigen and antibody |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113295862A (en) * | 2020-02-21 | 2021-08-24 | 深圳麦科田生物医疗技术股份有限公司 | Kit and method for detecting novel coronavirus SARS-CoV-2 antibody based on antigen marker |
| CN111796105A (en) * | 2020-07-30 | 2020-10-20 | 中国农业科学院兰州兽医研究所 | Magnetic particle chemiluminescence antibody detection kit for African swine fever virus and application thereof |
| CN111999494A (en) * | 2020-08-18 | 2020-11-27 | 北京贝尔生物工程股份有限公司 | Kit for detecting adenovirus IgM antibody by magnetic particle chemiluminescence method and preparation method thereof |
| CN111999495A (en) * | 2020-08-18 | 2020-11-27 | 北京贝尔生物工程股份有限公司 | Kit for detecting Coxsackie group B virus IgM antibody by magnetic particle chemiluminescence method and preparation method thereof |
| CN112433050A (en) * | 2020-11-04 | 2021-03-02 | 上海赛罕生物技术有限公司 | Chlamydia pneumoniae IgM antibody detection kit and detection method thereof |
| CN115047193A (en) * | 2022-06-27 | 2022-09-13 | 上海凯创生物技术有限公司 | Method for detecting trace amount of drugs in sewage |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN109444427A (en) | A kind of kit detecting human parvovirus IgM antibody | |
| US11959912B2 (en) | Fluorescence immunochromatographic detection card and a preparation method therefor and use thereof | |
| CN108152512A (en) | Heparin-binding protein detection kit and preparation method thereof | |
| WO2004088311A1 (en) | Diluent for norovirus or sapovirus specimen and method for detecting virus | |
| CN106443018A (en) | Myoglobin monoclonal abzyme marking compound and preparation method thereof and detection test kit | |
| CN108169219A (en) | A kind of kit and preparation method for quantitatively detecting serum amyloid A protein | |
| CN106370860A (en) | Kit and test paper strip for serum immunoglobulin E colloidal gold chromatography quantitative detection | |
| CN109307766A (en) | Pepsinogen I detection kit | |
| NO149864B (en) | IMMUNOLOGICAL REAGENT. | |
| CN109917138A (en) | A kind of myoglobins time-resolved fluoroimmunoassay measurement in chromatography kit | |
| CN109212193A (en) | Kit for clinical detection abnormal prothrombin | |
| JP6901719B2 (en) | Test method and test reagent for intrahepatic cholangiocarcinoma | |
| CN111239404B (en) | Detection kit capable of simultaneously detecting retinol binding protein in urine sample and serum sample | |
| CN116466078A (en) | Detection kit of anti-MDA 5 antibody and preparation method thereof | |
| CN107478853B (en) | A kind of apolipoprotein B detection kit and detection method | |
| CN105891497A (en) | Procalcitonin collaurum immune colorimetric determination detection kit and preparation method thereof | |
| CN109444428A (en) | A kind of kit of quantitative detection human parvovirus IgG antibody | |
| CN107490697B (en) | A kind of kit for testing prealbumin and detection method | |
| CN107462730B (en) | A kind of Complement C4 detection kit and detection method | |
| CN107478854B (en) | A kind of lipoprotein a detection kit and detection method | |
| CN110456044A (en) | A kind of kit for prostatitis detection | |
| CN105203773A (en) | Quantitative detection kit for human Dickkopf-1 protein (DKK-1) | |
| WO2022065398A1 (en) | Ferritin measuring reagent | |
| RU2800607C1 (en) | Elisa test system for the detection of antibodies to blv in blood serum and milk of cattle | |
| CN106932570A (en) | A kind of kit for detecting PSA PSA and its application |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20190308 |